By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Paratek Pharmaceuticals, Inc. 

75 Park Plaza
4th Floor
Boston  Massachusetts  02116  U.S.A.
Phone: 617-807-6600 Fax: 617-275-0039


Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Paratek's lead product candidate, omadacycline, is the first in a new class of tetracyclines known as aminomethylcyclines, with broad-spectrum activity against Gram-positive, Gram-negative and atypical bacteria.

Omadacycline is a new once-daily oral and IV, well-tolerated broad spectrum antibiotic being developed for use as empiric monotherapy for patients suffering from serious community-acquired bacterial infections, such as acute bacterial skin and skin structure infections, community acquired bacterial pneumonia, urinary tract infections and other community-acquired bacterial infections, particularly when antibiotic resistance is of concern to prescribing physicians.

Paratek's second Phase 3 product candidate, sarecycline, is a well-tolerated, once-daily, oral, narrow spectrum tetracycline-derived antibiotic with potent anti-inflammatory properties for the potential treatment of acne and rosacea in the community setting. Allergan owns the U.S. rights for the development and commercialization of sarecycline. Paratek retains all ex-U.S. rights. Allergan initiated two identical Phase 3 registration studies in December 2014 for sarecycline for the treatment of moderate to severe acne vulgaris. Top line data are expected in the first half of 2017.

Board of Directors
Michael F. Bigham
Chairman of the Board and Chief Executive Officer

Evan Loh, MD
Director and President, Chief Medical Officer

Thomas J. Dietz, Ph.D.

Timothy Franson, M.D.,

Richard Lim

Kristine Peterson

Robert Radie

Jeffrey Stein, Ph.D.

Last Updated: 04-23-02

Key Statistics

Ownership: Public

Web Site: Paratek Pharma
Employees: 76
Symbol: PRTK




Tufts University 

Company News
Paratek Pharma (PRTK) Reports Second Quarter 2017 Financial Results And Provides Clinical Update 8/2/2017 1:25:17 PM
Paratek Pharma (PRTK) Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) 8/1/2017 1:43:28 PM
Paratek Pharma (PRTK)'s Antibiotic Meets All Endpoints in Late-Stage Study 7/18/2017 7:12:46 AM
New Microbiology Data Reinforce Activity Of Paratek Pharma (PRTK)’s Omadacycline Against Pathogens Of Importance In Respiratory, Skin And Urinary Tract Infections 6/5/2017 1:52:15 PM
Paratek Pharma (PRTK) To Present New Data From Omadacycline Development Program At ASM Microbe 2017 5/24/2017 12:20:10 PM
Paratek Pharma (PRTK) Announces Completion Of Enrollment For Oral-Only Omadacycline Phase III Skin Study, Top-Line Data Expected In Mid-July 5/8/2017 10:39:28 AM
Paratek Pharma (PRTK) Reports First Quarter 2017 Financial Results And Provides Clinical Update 5/4/2017 11:53:44 AM
Paratek Pharma (PRTK) To Report First Quarter 2017 Financial Results And Provide Update On Clinical Progress On May 4, 2017 4/26/2017 10:41:36 AM
Zai Lab Acquires China Rights To Novel Antibiotic From Paratek Pharma (PRTK) 4/25/2017 12:27:12 PM
Paratek Pharma (PRTK) Release: Omadacycline Concentrations Exceed Tigecycline Levels In Lungs And Epithelial Lining Fluid According To Pharmacokinetic/Pharmacodynamic (PK/PD) Data 4/25/2017 8:52:11 AM